Browse the evidence

Obesity drives systemic inflammation through adipose tissue secretion of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6), which directly contributes to cardiovascular disease risk factors including atherosclerosis, hypertension, and insulin resistance.

If you have excess body fat, especially around your midsection, your body is actively releasing inflammatory chemicals that damage your blood vessels and increase your risk of heart disease and diabetes. Losing weight, particularly through diet and exercise, reduces this inflammation and lowers your cardiovascular risk, independent of just lowering cholesterol.

Chronic low-grade inflammation is a causative mechanism for insulin resistance and metabolic disease in obesity, rather than merely a consequence.

If you are overweight, your body may be in a state of chronic, low-grade inflammation that actively interferes with how your cells respond to insulin. This isn't just 'being fat'; it's a biological shift that promotes metabolic disease. Addressing this requires looking beyond simple calorie counting to strategies that may reduce this inflammatory burden, such as improving diet quality and managing stress, as the inflammation itself drives insulin resistance.

Higher baseline abundance of the gut bacterium Akkermansia muciniphila is associated with improved insulin sensitivity and metabolic health in overweight and obese adults, and predicts greater improvement in glucose homeostasis following calorie restriction.

If you are overweight or obese, your natural gut health, specifically the levels of Akkermansia muciniphila, may determine how effectively a calorie-restricted diet improves your metabolic health. While you cannot directly control this bacteria yet, maintaining a diet rich in fibers and proteins (as used in the study) may support a healthier microbiome ecosystem that favors these beneficial bacteria.

Adiponectin levels are inversely correlated with obesity and insulin resistance, and its deficiency contributes to insulin resistance, while its overexpression improves insulin sensitivity.

Lifestyle interventions that increase adiponectin (such as exercise and weight loss) are beneficial. Since adiponectin is low in obesity, improving metabolic health involves restoring this protective hormone.

Subcutaneous semaglutide at 0.4 mg daily significantly improves histologic resolution of NASH without worsening fibrosis in patients with stage F2 or F3 fibrosis compared to placebo.

For patients with NASH and fibrosis stages F2 or F3, treatment with 0.4 mg of subcutaneous semaglutide daily for 72 weeks significantly increases the likelihood of NASH resolution without worsening fibrosis compared to placebo. This benefit comes with a higher risk of gastrointestinal side effects, particularly nausea, which often diminishes over time. Patients should be counseled on nutrition and physical activity alongside this treatment.

Aging is associated with a progressive loss of neuromuscular function, specifically a 20-40% decrease in maximal voluntary contractile strength by the seventh and eighth decades, primarily driven by decreased muscle mass rather than reduced neural activation.

If you are in your 70s or 80s, expect your strength to be 20-40% lower than when you were young, mostly because you have less muscle. However, this loss is not permanent or unchangeable. Engaging in resistance training can help you regain strength and maintain independence, even at an advanced age.

Sleep disruption (fragmentation/continuity loss) causes increased sympathetic nervous system activity and HPA axis activation, leading to short-term stress responsivity and long-term cardiovascular disease risk.

Prioritize sleep continuity, not just duration. If you wake up frequently, your body experiences a stress response similar to being awake, increasing long-term risks for heart disease and high blood pressure. Focus on strategies to maintain uninterrupted sleep, such as managing environmental factors (light/noise) and addressing underlying sleep disorders like apnea.

Sleep disruption leads to metabolic dysregulation (decreased insulin sensitivity, altered leptin/ghrelin) increasing the risk of obesity, metabolic syndrome, and type 2 diabetes.

Poor sleep disrupts the hormones that control hunger (ghrelin increases, leptin decreases) and reduces your body's ability to use insulin. This makes you more likely to gain weight and develop type 2 diabetes, even if your diet and exercise habits haven't changed. Fixing sleep continuity is a key metabolic intervention.

Initiating postmenopausal hormone therapy (conjugated equine estrogens with or without medroxyprogesterone acetate) within 10 years of menopause onset is associated with a reduced risk of coronary heart disease (CHD), whereas initiating therapy 20 or more years after menopause increases CHD risk.

If you are considering hormone therapy for menopausal symptoms, the timing matters significantly for heart disease risk. Starting therapy within 10 years of menopause may lower your risk of coronary heart disease, but starting more than 20 years after menopause may increase that risk. However, note that stroke risk appears to increase regardless of when you start. Discuss your specific cardiovascular risk factors and the timing of menopause with your doctor to weigh the benefits of symptom relief against these risks.

Postnatal catch-up growth (defined as a weight SD score gain >0.67 between birth and two years) in children who were small or thin at birth is a significant risk factor for increased body mass index, percentage body fat, and central fat distribution (waist circumference) by five years of age.

If your baby was born small or thin but gains weight rapidly during the first two years of life, they are at a higher risk of being overweight or having higher body fat by age five. This does not mean you should restrict food, but it suggests that monitoring their growth trajectory and maintaining a healthy lifestyle as they grow is important to mitigate long-term metabolic risks.

Weight loss of 4–10 kg in obese subjects significantly reduces LDL-C by approximately 12% and increases LDL receptor mRNA levels by 27%.

Losing 4 to 10 kg of body weight can significantly improve your cholesterol profile, specifically lowering LDL-C by about 12%. This is achieved through a combination of calorie restriction and exercise, which improves your body's ability to clear LDL from the blood by increasing LDL receptor activity.

In type-2 diabetic patients, synthetic human GLP-1 [7-36 amide] retains significant insulinotropic activity and lowers glucagon, whereas synthetic human GIP loses its insulin-stimulating effectiveness.

For individuals with type-2 diabetes, medications that mimic GLP-1 (like semaglutide or liraglutide) are effective because they bypass the body's broken natural response to food. Unlike GIP, which stops working well in diabetes, GLP-1 continues to help produce insulin and lower glucagon, helping to control blood sugar without causing dangerous lows.

An elevated dietary omega-6/omega-3 fatty acid ratio (approaching 20:1 in Western diets) increases the risk of obesity by promoting systemic inflammation, inhibiting adipose tissue browning, and hyperactivating the endocannabinoid system.

To reduce obesity risk, prioritize lowering your omega-6 intake (found in many vegetable oils like soybean, corn, and sunflower oil) rather than just increasing omega-3s. Aim to lower your omega-6/omega-3 ratio from the typical Western 20:1 toward 4:1 or lower. This involves reducing processed foods and seed oils while increasing sources of omega-3s like fatty fish or algae.

Higher habitual salt intake is associated with a significantly increased risk of stroke and total cardiovascular disease.

Reduce your daily salt intake by approximately 5 grams (about one teaspoon). This reduction is associated with a 23% lower risk of stroke and a 17% lower risk of cardiovascular disease. Focus on reformulating foods or choosing lower-sodium options rather than just adding less salt at the table.

The association between salt intake and stroke risk is dose-dependent, with a 6% increase in stroke rate for every 50 mmol/day difference in sodium intake.

Every 50 mmol (approx 1.2g salt) of sodium you consume above your baseline adds about 6% to your stroke risk. Reducing intake incrementally yields proportional benefits.

Visceral adipose tissue (VAT) is the primary driver of insulin resistance and metabolic syndrome features, whereas subcutaneous fat acts as a protective metabolic sink; excess VAT leads to ectopic fat deposition in the liver and muscle, causing atherogenic dyslipidemia and inflammation.

Stop relying on BMI or scale weight to judge your metabolic health. Focus on waist circumference as a primary metric. If you have a large waistline, you likely have visceral fat, which drives insulin resistance and heart disease risk. Lifestyle changes that reduce waist size (even without major weight loss) are more effective for metabolic health than those that only affect total body weight.

The 'Hypertriglyceridemic Waist' phenotype (elevated waist circumference combined with high fasting triglycerides) is a simple, effective clinical marker for identifying visceral obesity and insulin resistance, superior to BMI or waist circumference alone.

If you have a large waist, check your fasting triglycerides. If both are high, you likely have visceral fat and insulin resistance, even if your BMI is normal. This 'Hypertriglyceridemic Waist' is a strong signal to prioritize lifestyle changes to reduce visceral fat.

Combined oral contraceptive pills (COCP) are the first-line pharmacological management for menstrual irregularity and hyperandrogenism in women with PCOS.

If you have irregular periods or signs of high androgens (like hirsutism), combined oral contraceptives are the recommended first medication. Low-dose versions are preferred.

Short sleep duration is associated with hormonal changes that increase hunger, specifically suppressed leptin and elevated ghrelin levels.

If you are struggling with hunger, check your sleep. Short sleep changes your hormones (leptin and ghrelin) to make you feel hungrier. Getting 7-8 hours of sleep can help regulate these hormones and reduce cravings.

SGLT2 inhibitors (e.g., Canagliflozin, Dapagliflozin, Empagliflozin) lower blood glucose through an insulin-independent mechanism by blocking glucose reabsorption in the kidneys, providing modest weight loss and blood pressure reduction.

SGLT2 inhibitors are oral medications that help your kidneys remove sugar from your body through urine. This lowers blood sugar without relying on insulin, making them useful even in advanced diabetes. They also help with weight and blood pressure. Watch for signs of urinary or genital infections.

Subcutaneous recombinant leptin administration induces a dose-dependent reduction in body weight and fat mass in both lean and obese adults, with the majority of weight loss attributable to fat loss.

Daily subcutaneous injections of recombinant leptin can lead to significant fat loss in both lean and obese adults, with higher doses producing greater weight reduction. While the treatment is effective, it requires daily injections and may cause local skin reactions, though these are typically manageable.

Prolonged sleep deficiency (short duration or disturbance) causes chronic, systemic low-grade inflammation, which is associated with increased risk of inflammatory diseases such as diabetes, atherosclerosis, and neurodegeneration.

Prioritize consistent, sufficient sleep duration and quality. Chronic sleep loss is not just about feeling tired; it actively drives systemic inflammation, increasing your risk for diabetes, heart disease, and neurodegeneration. Treat sleep as a non-negotiable pillar of immune health, equal in importance to nutrition and exercise.

Adequate sleep enhances host defense by improving infection outcomes and vaccination responses, mediated by the induction of a hormonal constellation that supports immune functions.

Ensure you get adequate sleep, especially around the time of vaccination or when you suspect an infection. Sleep actively boosts your immune response, improving vaccine efficacy and helping your body fight off pathogens more effectively. Prioritizing sleep is a proactive strategy for immune resilience.

Targeted colonic delivery of propionate via an inulin-propionate ester reduces acute energy intake and prevents long-term weight gain and intra-abdominal fat accumulation in overweight adults.

For overweight adults struggling with gradual weight gain, a specific supplement delivering propionate directly to the colon (10g/day) can help reduce hunger and prevent weight gain over 6 months. It works by triggering satiety hormones (PYY and GLP-1) in the gut. This is distinct from simply eating more fiber, which can cause digestive issues. Consult a doctor before starting, especially if you have liver conditions like NAFLD, as it may also reduce liver fat.